uniQure Inks $2 Billion Licensing Deal With CSL Behring

In exchange for up to $2.1 billion plus royalties on sales, uniQure (NASDAQ: QURE) licensed the global commercialization rights for its hemophilia B gene therapy, etranacogene dezaparvovec, to CSL Behring (OTC: CSLLY) on Wednesday. 

Etranacogene dezaparvovec is a clinical-stage gene therapy that could significantly disrupt hemophilia B treatment. A hereditary disorder, hemophilia B prevents patients from producing adequate levels of blood clotting factor IX, resulting in significant risk of uncontrolled bleeding events and requiring a lifetime of regular infusions.

Image source: Getty Images.

Continue reading

Source Fool.com